Download Files:
Products Details
Product Description
– CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor (IC50: 7.4 nM). CDK7-IN-26 potently inhibits the growth of triple-negative breast cancer (TNBC) cell line-derived xenograft (CDX) tumors in vivo and inhibits MDA-MB-453 cells in vitro with an IC50 of 0.15 μM[1].
Web ID
– HY-157210
Shipping
– Room temperature
Molecular Formula
– C22H22FN6OPS
References
– [1]Zhang H et al. Discovery and optimization of thieno [3, 2-d] pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7[J]. European Journal of Medicinal Chemistry, 2023: 115955.
Molecular Weight
– 468.49
SMILES
– O=P(C)(C1=C(C=CC2=C1NC=C2C3=NC(N[C@H]4C[C@H](F)CNC4)=NC5=C3SC=C5)C#N)C
Clinical Information
– No Development Reported
Research Area
– cancer
Solubility
– 10 mM in DMSO
Target
– CDK
Pathway
– Cell Cycle/DNA Damage
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
